34 completed, 24 recruiting, 12 terminated, 9 active not recruiting. 90 Phase 2, 14 Phase 3, 12 Phase 1.
Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old Felzartamab, Placebo - Generalized Myasthenia Gravis | Phase 2 | Not yet recruiting | Biogen | 75 | 2026-11-19 | 2026-11-16 |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) Ublituximab, Placebo - Myasthenia Gravis | Phase 2 | Recruiting | TG Therapeutics, Inc. | 120 | 2026-11-01 | 2026-10-29 |
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-19 | 2026-11-17 |
| A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis SHR-2173 injection, Placebo - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 60 | 2026-08-28 | 2026-10-22 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Inebilizumab - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Amgen | 15 | 2026-07-21 | 2026-10-23 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-11-16 |
| Efgartigimod in Anti-NMDA Receptor Encephalitis. Efgartigimod Alfa - Encephalitis Autoimmune | Phase 2 | Recruiting | Beijing Tongren Hospital | 20 | 2026-06-25 | 2026-09-16 |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Povetacicept, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 34 | 2026-05-13 | 2026-10-29 |
| Study of Aritinercept in Patients With Generalized Myasthenia Gravis Aritinercept, Placebo - Myasthenia Gravis, Generalized | Phase 1 / Phase 2 | Recruiting | Aurinia Pharmaceuticals Inc. | 81 | 2026-04-22 | 2026-08-03 |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis IM-101 Part A, Placebo Part A, IM-101 Part B - Myasthenia Gravis | Phase 1 / Phase 2 | Recruiting | ImmunAbs Inc. | 96 | 2026-02-05 | 2026-02-11 |
| Ripertamab for the Treatment of Myasthenia Gravis ripertamab - Myasthenia Gravis (MG) | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 20 | 2026-02-01 | 2026-01-28 |
| Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 15 | 2026-01-14 | 2026-02-11 |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Efgartigimod IV, Empasiprubart IV - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis | Phase 2 | Recruiting | argenx | 70 | 2025-12-19 | 2026-09-24 |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis YTB323 - Generalized Myasthenia Gravis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 15 | 2025-04-22 | 2026-09-04 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| Blinatumomab for Treatment of Refractory Myasthenia Gravis Blinatumomab - Myasthenia Gravis | Phase 2 / Phase 3 | Not yet recruiting | Da, Yuwei, M.D. | 2 | 2025-04-01 | 2025-03-25 |
| Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy Immunoglobulins IV (CLAYRIG), Cyclophosphamide IV, Methylprednisolone IV - Paraneoplastic Sensory Neuronopathy | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 21 | 2025-01-10 | 2025-02-17 |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis CABA-201 - Generalized Myasthenia Gravis (gMG) | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 24 | 2024-12-17 | 2026-10-19 |
| Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis Taitacept - Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 2 | Recruiting | Beijing Tongren Hospital | 10 | 2024-12-01 | 2024-11-20 |
Showing 20 of 90. Sign in to see all of them.
Myasthenia Gravis (58) · ACTH Syndrome, Ectopic (12) · Cushing Syndrome (10) · Zollinger-Ellison Syndrome (6) · Myelitis, Transverse (5) · Autoimmune Diseases (4) · Neuromyelitis Optica (4) · Pituitary ACTH Hypersecretion (4) · Adrenal Cortex Neoplasms (3) · Adrenal Hyperplasia, Congenital (3) · Anti-N-Methyl-D-Aspartate Receptor Encephalitis (3) · Autoimmune Diseases of the Nervous System (3) · Diabetes Mellitus, Type 2 (3) · Gastrinoma (3) · Opsoclonus-Myoclonus Syndrome (3)
Neoplasms (90) · Neoplasms by Site (80) · Nervous System Diseases (76) · Nervous System Neoplasms (72) · Neurodegenerative Diseases (71) · Paraneoplastic Syndromes, Nervous System (71) · Immune System Diseases (68) · Autoimmune Diseases of the Nervous System (65) · Autoimmune Diseases (64) · Neuromuscular Diseases (60) · Neuromuscular Junction Diseases (59) · Paraneoplastic Endocrine Syndromes (18) · Central Nervous System Diseases (17) · Endocrine System Diseases (16)
Rituximab (6) · efgartigimod alfa (3) · Hizentra (2) · Immunoglobulins, Intravenous (2) · Metyrapone (2) · Osilodrostat (2) · eculizumab (2) · gamma-Globulins (2) · pasireotide (2) · relacorilant (2) · rozanolixizumab (2) · zilucoplan (2) · 4-Aminopyridine (1) · ASP3662 (1) · Albuterol (1)
argenx (6) · Alexion Pharmaceuticals, Inc. (4) · Novartis Pharmaceuticals (4) · Assistance Publique - Hôpitaux de Paris (3) · Mayo Clinic (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Tang-Du Hospital (3) · Beijing Tongren Hospital (2) · Corcept Therapeutics (2) · CuraVac (2) · Grifols Therapeutics LLC (2) · Momenta Pharmaceuticals, Inc. (2) · Sparrow Pharmaceuticals (2) · UCB Biopharma SRL (2) · American University of Beirut Medical Center (1)
United States (62) · Canada (24) · Italy (20) · Poland (20) · Germany (17) · Spain (17) · Belgium (15) · France (14) · United Kingdom (13) · Netherlands (11) · China (9) · Japan (7) · Denmark (6) · Serbia (6) · Czechia (5)
Irina Bancos, MD (2) · Rudy Mercelis, MD, PhD (2) · Andreas G Moraitis, MD (1) · Andreas Meisel, Prof. Dr. (1) · Andrew Wolff, MD, FACC (1) · Antonio Guglietta, MD (1) · Benjamin Greenberg, MD (1) · Charles M. Epstein, M.D. (1) · Chongbo Zhao (1) · Dimitri Psimaras, MD (1) · Falk Hiepe, Prof. Dr. (1)
PMID 35350948, PMID 19838774, PMID 20606544, PMID 21211990, PMID 23512355, PMID 25956795, PMID 26539981, PMID 28801338, PMID 30130439, PMID 32065623, PMID 32098874, PMID 33219142, PMID 34335465, PMID 34857535, PMID 35058882, PMID 35412216, PMID 36270895, PMID 37166675, PMID 37259693, PMID 37353270, PMID 37353278, PMID 38099334, PMID 38165333, PMID 39720510, PMID 40320172, PMID 40913424, PMID 41224659, PMID 41514038, PMID 41514039, PMID 42043793
2025 (6), 2023 (4), 2016 (2), 2018 (2), 2019 (2), 1RC3NS070670-01 (1), 2008 (1), 2015 (1), 2017 (1), N01CM62202 (1), P30CA016672 (1), U01CA062490 (1), U01NS077179 (1), U01NS077352 (1), U01NS084495 (1)